Clinical Trials Logo

Clinical Trial Summary

The aim of the project is to study the feasibility of implementing a novel point-of-care test (POCT) for rapid detection of SARS-CoV-2 infection. A CRISPR-based detection kit would be piloted for testing of suspected SARS-CoV-2 infection in healthcare setting, with the objectives of evaluating the performance of the new test in the detection of SARS-CoV-2, and assessing the practicability of the new test for diagnosing SARS-CoV-2 infection in healthcare settings.


Clinical Trial Description

A CRISPR-based lateral flow assay (LFA) detection kit would be designed and developed for testing for the presence of SARS-CoV-2. The aim of the project is to study the feasibility of implementing the novel point-of-care test (POCT) for rapid detection of SARS-CoV-2 infection in health service setting, with the following objectives: (b) Evaluation of the performance of novel POCT in comparison with conventional quantitative PCR in diagnosis SARS-CoV-2 infection and (c) Assessment of the practicability of LFA-CRISPR-based tests in the operating environments in healthcare settings. Patients who are admitted to the isolation wards of Prince of Wales Hospital, Hong Kong would be invited to join the study. A total of 600 persons with suspected SARS-CoV-2 infection presenting with different symptomatology and epidemiological history will be recruited. Nasal, deep saliva and/or mouth gargle samples will be collected from all recruited subjects in accordance with standard clinical protocol. The samples would be tested for SARS-CoV-2 by the new Point-of-care test, in parallel with standard diagnostic testing of the hospital. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05034978
Study type Observational
Source Chinese University of Hong Kong
Contact Shui Shan Lee, MD
Phone 85261703177
Email [email protected]
Status Recruiting
Phase
Start date March 16, 2021
Completion date September 15, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT04999098 - Clinical Study to Assess the Antiviral Properties of Echinaforce Reducing Oropharyngeal Concentration and Infectivity of SARS-CoV2 Phase 4
Not yet recruiting NCT04978038 - Third Dose of COVID-19 Vaccine in LTCF Residents Phase 4
Not yet recruiting NCT04528771 - S-Nitrosylation Therapy of COVID-19 Phase 1
Not yet recruiting NCT05030974 - RECOVAC Booster Vaccination Study Phase 4
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Not yet recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Recruiting NCT04953039 - Use of Saliva for COVID-19 Diagnosis
Recruiting NCT04918797 - COVAXIN in a Pediatric Cohort Phase 2/Phase 3
Completed NCT04893694 - the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection
Recruiting NCT04883190 - Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial
Active, not recruiting NCT04916821 - Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19) N/A
Recruiting NCT04953091 - Evaluation of the Sofia SARS Antigen FIA Assay for COVID-19
Active, not recruiting NCT04889365 - COVID-19 Antigen Rapid Test Kit
Recruiting NCT04907331 - Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 Phase 2
Enrolling by invitation NCT05038475 - Clinical and Immunological Responses After SARS-CoV-2 Infection Causing COVID-19
Recruiting NCT04948190 - Canine COVID-19 Detection Phase 2 and 3
Completed NCT04916574 - Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum N/A
Enrolling by invitation NCT04887246 - Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia